

OIPE MASSIE

MAIL STOP - PCT Docket No.: 27579U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: ROSCHER, et al.

Art Unit: XX

Appl. No.: 10/589,871

Examiner: XX

Appl. Filing Date: August 18, 2006

Confirm. No.: XX

Intl. Appl. No.: PCT/EP2005/050799

Intl. Appl. Filing Date: February 25, 2005

For: CICLESONIDE AND GLYCOPYRRONIUM COMBINATION

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1. Information Disclosure Statement; and
- 2. PTO Form-1449 with 48 references cited, and copies of 34 of the 48 references cited.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.


Respectfully submitted, NATH & ASSOCIATES PLLC

November 22 , 2006

Gary M. Nath, Reg. No. 26,965

Sheldon M. McGee, Reg. No. 50,454

Customer No. 34375





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: ROSCHER, et al. Art Unit: XX

Appl. No.: 10/589,871 Examiner: XX

Appl. Filing Date: August 18, 2006 Confirm. No.: XX

Intl. Appl. No.: PCT/EP2005/050799

Intl. Appl. Filing Date: February 25, 2005

For: CICLESONIDE AND GLYCOPYRRONIUM COMBINATION

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

- a. [XXX] The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- b. [] The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

- [] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
- [] ii. a check in the amount required by 37 C.F.R. 1.17(p).

- c. [] The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.
 - [] Certification report(e) below; and
 - [] a check in the amount as required by 1.17(p).
- d. [] The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.
- e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]
 - [] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R.

1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

<u>or</u>

- [] Appropriate certification is attached.
- f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

g. [\mathbf{XX}] Copies of the documents are attached herewith with a completed PTO Form-1449.

or

[] Copies of the documents are not attached, with a completed PTO Form-1449 as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and / or

[XXX] Copies of US Patents/Publications not attached, with a completed PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted, NATH & ASSOCIATES PLLC

November 22 , 2006

Gary M. Nath, Reg. No. 26,965

Sheldon M. McGee, Reg. No. 50,454

Customer No 34375

Le

of 2 Page 1

Docket No.: 27579U THATE TRADE nventor: ROSCHER, et al. PTO FORM-1449 Appl. No.: Intl. Appl. No: Art Unit: 10/589,871 PCT/EP2005/050799 XX INFORMATION DISCLOSURE Appl. Filing Intl. Appl. Filing Examiner: XX CITATION Date: Date: August 18, 2006 February 25, 2005 Confirm. No: U.S. PATENT DOCUMENTS Filed Date Exam. Document No. Issue/Public. Date Inventor Initial /D.W. 2005/0026886 2/3/2005 7/15/2004 Α1 Meade et al. A2 2005/0175548 8/11/2005 Goede et al. 2/7/2005 /D.W./ 10/16/2001 Dvorsky et al. 4/20/2000 АЗ 6,302,331 D.W.//D.W./ 6,645,466 11/11/2003 Keller et al. 11/10/1999 Α4 6,204,285 3/20/2001 6/27/1997 Fabiano et al. **A5** /D.Wøj.W. **A6** 6,454,193 9/24/2002 Busick et al. 4/20/2000 6,397,838 6/4/2002 12/21/1999 /D.W./ Α7 Zimlich Jr. et al. 5,263,475 11/23/1993 Altermatt et al. 3/18/1992 **A8** /D.W./(corresp. to EP0505321) A9 2004/0266869 12/30/2004 12/12/2001 /D.W./ Montaque et al. (corresp. to W00247668) A10 5,482,934 1/9/1996 Calatayud et al. 7/20/1994 /D.W./ (corresp. to DE4129535) 3/31/1994 A11 5,733,901 3/31/1998 Gutterer /D.W./ (corresp. to W09422899) 6,307,060 10/23/2001 5/11/1999 A12 Noe et al. /D.W./(corresp. to WO9821183) 9/24/2002 5/9/2000 A13 Bozung et al. /D.W./6,455,524 (corresp. to W00069468) 11/5/2002 8/2/1999 A14 6,475,467 Keller et al. /D.W./ (corresp. to W00007567) FOREIGN PATENT DOCUMENTS Document No. Public. Date Country Translation Exam. Initial 5/10/2002 WO Abstract A15 02/36106 A2 DMLA16 0 725 725 B1 8/14/1996 EPN/A 02/083113 A2 10/24/2002 WO N/A A17 A18 0 505 321 A2 9/23/1992 ΕP No /D.W./ WO A19 02/47668 A2 6/20/2002 Abstract 7D.W.7 GB N/A A20 247,680 2/25/1926 /D.W. A21: 41 29 535 A1 3/12/1992 DE No /D.W./ 2006/003078 A1 1/12/2006 WO N/A A22 N/A /D.W./ A23 95/02650 A1 1/26/1995 WO WO /D.W./ A24 94/22899 A1 10/13/1994 Abstract $\overline{\mathsf{wo}}$ 70.W.7 A25 8/8/1991 Abstract 91/11495 A1 /D.W./ A26 93/11743 A1 6/24/1993 WO N/A N/A 10/3/1991 WO /D.W./ A27 91/14422 A1 N/A /D.W./ 4/4/1991 WO A28 91/04011 A1 /D.W./ 8/8/1991 WO N/A A29 91/11173 A1 N/A 7D.W./ WO A30 98/52542 A1 11/26/1998 /D.W. A31 553 298 B1 8/4/1993 EΡ N/A /D.W./ N/A EΡ A32 372 777 B1 6/13/1990 /D.W./ 98/00133 A1 1/8/1998 WO N/A A33 /D.W./ WO Abstract A34 98/21183 A1 5/22/1998 7D.W./ N/A A35 98/00132 A1 1/8/1998 WO /D.W./ N/A 10/18/2001 WΟ A36 01/76575 A2 7U.W.7 02/30394 A2 4/18/2002 WO N/A A37 /D.W./ ΕP N/A 1/9/1991 407 028 B2 A38 N/A /D.W. A39 1/17/1996 EΡ 0 691 865 В1 5/3/1995 ΕP N/A /D.W./ A40 650 410 B1

MAIL	STOP	-	PCT
1	^-		

Page 2	of	2			2 2 2006	Dock	tet No.: 27579U		
/D.W./	A41	00/69468 A1	11/23/20	3	الخ	WO	Abstract		
/D.W./	A42	92/11190 A2	7/9/1992		.5/	WO	N/A		
/D.W./	A43	96/32150 A1	10/17/1996		DEMARK	WO	N/A		
7,D.W./	A44	00/07567 A1	2/17/2000			WO	Abstract		
/D.W./	A45								
OTHER									
Exam. Initial	(Including Author, Title, Date, Pertinent Pages, etc.)								
/D.W./	A46	Mirakhur, R.K., et al., "Glycopyrrolate: pharmacology and clinical use", Anaesthesia, Vol. 38, pg. 1195-1204, (1983).							
/D.W./	A47	Levin, R.M., et al., "Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder", The Journal of Urology, Vol. 128, pg. 396-398, (1982).							
/D.W./	A48	Cooke, R.D., "Glycopyrrolate in bladder dysfunction", SA Medical Journal, Vol. 63, pg. 3, (1983).							
/D.W./	A49	Demian, J., et al., "High-Performance Liquid Chromatographic Separation of 3-[(Cyclopentylhydroxyphenyl-acetyl)oxy]-1,1-Dimethyl-pyrrolidinium Bromide Diastereomers", Journal of Liquid Chromatography, Vol. 13, No. 4, pg. 779-787, (1990).							
Examiner					· Date (Considered			
/David Webster/				2/10/2009					
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.									